This steroid is quite confusing to me, as it was found to be a good treatment for hyperlipemia (it lowers cholesterol), and this was without affecting proteinuria (the prevention of excretion of amino acids). Generally, steroids affect proteinuria positively, as you'd expect (and want) them to. This stuff is DHT-derived, and it also appears to have a relatively low androgen binding ability, which makes the lack of effect it had on proteinuria when compared with it's anabolic rating even more confusing. Furazabol is not estrogenic in any way.

It has become quite popular ever since its reappearance on many underground labs' price lists. Finding out information on this stuff was agonizing, since most of it is in Japanese, and no athletes really use it. Anyway, with respect to its half-life and active life (and detection time), I'm pretty much estimating from what I've seen in studies. One study said that the half-lives of unchanged Furazabol in two human subjects were 1.87 and 1.29 h respectively, and the recovered amount in 48 h was averaged to 24% (33% for one, 15% for the other, respectively). The really interesting thing about this stuff (to me, anyway) is that it's a DHT-derived steroid, with a decent anabolic rating that lowers cholesterol! It is often compared with Winstrol.

The effects of Miotolan (furazabol) are similar to Winstrol except instead of having an adverse effect on cholesterol values, therapeutic doses of Furazabol purportedly improve a person's blood lipid profile. As such, Furazabol was prescribed in Japan under the trade name Miotolan in the 1970s as a treatment for hypercholesterolemia.

According to William Llewellyn, author of Anabolics 2007, the cholesterol-lowering effects of Furazabol are a myth. In the 1970s, research studies showed that Furazabol along with many other orally-active AAS like Anavar (oxandrolone) lowered total serum cholesterol. It was subsequently established that the cholesterol reduction from oral AAS was the result of suppressed HDL levels. As such, it would be expected that Furazabol, like other oral anabolic steroids, while reducing total cholesterol levels would still adversely affect the HDL/LDL ratio and increase the risk of cardiovascular disease.

Diversion of this obscure pharmaceutical steroid to the black market rarely occurred while it was being manufactured by Daiichi Seiyaku Company in Japan. However, a number of underground labs (UGL) have produced limited quantities of Furazabol in recent years. Additionally, a non-methylated derivative of Furazabol called Furaguno is currently being sold over-the-counter on the sport nutrition market in the United States in 2006 and 2007.

Furazabol is an oral anabolic steroid derived from dihydrotestosterone. This agent is moderately anabolic, with only mild androgenic properties. Furazabol was a popular steroid among Olympic athletes during the 1980's, when it was quietly known among certain trainers that testing officials had not yet identified the agent, and therefore could not test for it. Today, furazabol is very scarcely known to bodybuilders. The Miotolan brand from Japan was discontinued many years ago, and no pharmaceutical preparation containing furazabol has been known to exist since. The drug is occasionally located on the black market, however, due to the fact that is it still produced in bulk (as a raw material for product manufacturing) in Asia. From there it is obtained by underground steroid manufacturing operations in the West, and produced into oral tablets and capsules. Furazabol is no longer produced as a prescription drug product.

Synthetic, orally active anabolic-androgenic steroid which has been marketed in Japan since 1969. Furazabol has a relatively high ratio of anabolic to androgenic activity.